We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Can 18 F-FDG PET/CT Radiomics Features Predict Clinical Outcomes in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma?
- Authors
Jayaprakasam, Vetri Sudar; Gibbs, Peter; Gangai, Natalie; Bajwa, Raazi; Sosa, Ramon E.; Yeh, Randy; Greally, Megan; Ku, Geoffrey Y.; Gollub, Marc J.; Paroder, Viktoriya
- Abstract
Simple Summary: PET/CT is an important staging modality in the baseline assessment of locally advanced esophageal squamous cell carcinoma. Accurate staging and response prediction in these patients is essential for management. The aim of this retrospective study was to assess the usefulness of 18F-FDG PET/CT radiomics features in predicting outcomes such as tumor and nodal categories, PET-based response to induction chemotherapy, progression-free survival, and overall survival. In a final cohort of 74 patients, we found that the developed radiomics models can predict these clinical and prognostic outcomes with reasonable accuracy, similar or better than those derived from conventional imaging. Future studies with a larger cohort would be helpful in establishing the significance of these models. This study aimed to assess the usefulness of radiomics features of 18F-FDG PET/CT in patients with locally advanced esophageal cancers (ESCC) in predicting outcomes such as clinical tumor (cT) and nodal (cN) categories, PET response to induction chemotherapy (PET response), progression-free survival (PFS), and overall survival (OS). Pretreatment PET/CT images from patients who underwent concurrent chemoradiotherapy from July 2002 to February 2017 were segmented, and data were split into training and test sets. Model development was performed on the training datasets and a maximum of five features were selected. Final diagnostic accuracies were determined using the test dataset. A total of 86 PET/CTs (58 men and 28 women, mean age 65 years) were segmented. Due to small lesion size, 12 patients were excluded. The diagnostic accuracies as derived from the CT, PET, and combined PET/CT test datasets were as follows: cT category—70.4%, 70.4%, and 81.5%, respectively; cN category—69.0%, 86.2%, and 86.2%, respectively; PET response—60.0%, 66.7%, and 70.0%, respectively; PFS—60.7%, 75.0%, and 75.0%, respectively; and OS—51.7%, 55.2%, and 62.1%, respectively. A radiomics assessment of locally advanced ESCC has the potential to predict various clinical outcomes. External validation of these models would be further helpful.
- Subjects
CONFIDENCE intervals; RETROSPECTIVE studies; HEALTH outcome assessment; TREATMENT effectiveness; CANCER patients; CHEMORADIOTHERAPY; POSITRON emission tomography; RADIOPHARMACEUTICALS; SURVIVAL analysis (Biometry); DESCRIPTIVE statistics; DEOXY sugars; PROGRESSION-free survival; RECEIVER operating characteristic curves; SENSITIVITY &; specificity (Statistics); SQUAMOUS cell carcinoma; ESOPHAGEAL cancer
- Publication
Cancers, 2022, Vol 14, Issue 12, p3035
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14123035